Article

Structure of a V3-containing HIV-1 gp120 core.

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
Science (Impact Factor: 31.48). 12/2005; 310(5750):1025-8. DOI: 10.1126/science.1118398
Source: PubMed

ABSTRACT The third variable region (V3) of the HIV-1 gp120 envelope glycoprotein is immunodominant and contains features essential for coreceptor binding. We determined the structure of V3 in the context of an HIV-1 gp120 core complexed to the CD4 receptor and to the X5 antibody at 3.5 angstrom resolution. Binding of gp120 to cell-surface CD4 would position V3 so that its coreceptor-binding tip protrudes 30 angstroms from the core toward the target cell membrane. The extended nature and antibody accessibility of V3 explain its immunodominance. Together, the results provide a structural rationale for the role of V3 in HIV entry and neutralization.

Download full-text

Full-text

Available from: Richard Wyatt, Jul 03, 2015
0 Followers
 · 
120 Views
  • Source
  • Source
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The conventional old treatment method for cancer therapy is associated with severe side effects along with several limitations. Therefore, searching and developing new methods for cancer became crucial. This chapter focuses on a relatively new method for cancer treatment named antibody directed enzyme prodrug therapy (ADEPT). This approach consists of two steps by which the first step involves an administration of antibody-drug activating enzyme conjugate (AEC) to target the tumor and to be accumulated predominantly at the tumor cells that have the wanted tumor associated antigen, and to be allowed to localize and clear the unbounded conjugate from the plasma. The second step involves a nontoxic prodrug which is injected systemically and is converted to its corresponding active form with high tumor concentration by the localized enzyme. The chapter describes in details the most used enzyme-antibody systems, their advantages and disadvantages.
    Prodrugs Design A New Era, 1 edited by Rafik Karaman, 07/2014: chapter VII: pages 233-277; Prodrugs Design (Pharmacology - Research, Safety Testing and Regulation)., ISBN: 978-1-63117-701-9